PureTech Health plc – NASDAQ:PRTC
PureTech Health stock price today
PureTech Health stock price monthly change
PureTech Health stock price quarterly change
PureTech Health stock price yearly change
PureTech Health key metrics
Market Cap | 485.66M |
Enterprise value | 254.58M |
P/E | 9.95 |
EV/Sales | 74.39 |
EV/EBITDA | 2.88 |
Price/Sales | 180.23 |
Price/Book | 1.08 |
PEG ratio | N/A |
EPS | -3.57 |
Revenue | 4.99M |
EBITDA | -211.29M |
Income | -98.22M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 1811.18% |
Oper. margin | -771.22% |
Gross margin | -458.88% |
EBIT margin | -771.22% |
EBITDA margin | -4231.29% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePureTech Health stock price history
PureTech Health stock forecast
PureTech Health financial statements
| Mar 2023 | 1.57M | -12.50M | -793.78% |
|---|---|---|---|
| Jun 2023 | 3.15M | -25.00M | -793.81% |
| Sep 2023 | 90K | -20.34M | -22607.22% |
| Dec 2023 | 178.56K | -40.36M | -22606.75% |
| 2025 | 36.75M | -191.05M | -519.86% |
|---|---|---|---|
| 2026 | 23.6M | -252.6M | -1070.34% |
| 2027 | 236.3M | -105.27M | -44.55% |
| 2028 | 482.8M | 15.47M | 3.2% |
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 0% |
|---|
| 2019 | 0% |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 |
| Mar 2023 | 693552000 | 184.66M | 26.63% |
|---|---|---|---|
| Jun 2023 | 693552000 | 184.66M | 26.63% |
| Sep 2023 | 693973000 | 235.74M | 33.97% |
| Dec 2023 | 693973000 | 125.58M | 18.1% |
| Mar 2023 | -32.56M | 86.94M | 45.94M |
|---|---|---|---|
| Jun 2023 | -65.13M | 173.88M | 91.89M |
| Sep 2023 | -20.39M | -52.44M | -6.87M |
| Dec 2023 | -39.94M | -105.44M | -14.37M |
PureTech Health alternative data
| Aug 2023 | 111 |
|---|---|
| Sep 2023 | 111 |
| Oct 2023 | 111 |
| Nov 2023 | 111 |
| Dec 2023 | 111 |
| Jan 2024 | 111 |
| Feb 2024 | 111 |
| Apr 2024 | 111 |
| May 2024 | 90 |
| Jun 2024 | 90 |
| Jul 2024 | 90 |
PureTech Health other data
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 266129542 | 0 |
| Jun 2023 | 0 | 0 |
| Sep 2023 | 0 | 0 |
| Quarter | Transcript |
|---|---|
| Q4 2023 25 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Ms. Daphne Zohar (1971) Founder, Chief Executive Officer & Executive Director | $1,240,000 |
Mr. Stephen M. Muniz J.D. (1970) Chief Operating Officer, Sec. & Executive Director | $874,240 |
| Dr. Robert S. Langer Jr. (1949) Co-Founder & Non-Executive Director | $245,000 |
Dr. Bennett M. Shapiro (1940) Co-Founder | $95,000 |
Mr. Spencer Ball Senior Vice President of HR | |
Dr. George Farmer Ph.D. Chief Financial Officer | |
Dr. David R. Elmaleh Co-Founder & Senior Advisor | |
Dr. Joseph B. Bolen Chief Scientific Officer | |
Dr. Bharatt M. Chowrira Pres, Chief of Bus. & Strategy and Executive Director | |
Ms. Allison Mead Talbot Head of Communications & Investor Relations |
-
What's the price of PureTech Health stock today?
One share of PureTech Health stock can currently be purchased for approximately $19.04.
-
When is PureTech Health's next earnings date?
Unfortunately, PureTech Health's (PRTC) next earnings date is currently unknown.
-
Does PureTech Health pay dividends?
No, PureTech Health does not pay dividends.
-
How much money does PureTech Health make?
PureTech Health has a market capitalization of 485.66M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 59.33% to 3.33M US dollars.
-
What is PureTech Health's stock symbol?
PureTech Health plc is traded on the NASDAQ under the ticker symbol "PRTC".
-
What is PureTech Health's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of PureTech Health?
Shares of PureTech Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are PureTech Health's key executives?
PureTech Health's management team includes the following people:
- Ms. Daphne Zohar Founder, Chief Executive Officer & Executive Director(age: 54, pay: $1,240,000)
- Mr. Stephen M. Muniz J.D. Chief Operating Officer, Sec. & Executive Director(age: 55, pay: $874,240)
- Dr. Robert S. Langer Jr. Co-Founder & Non-Executive Director(age: 76, pay: $245,000)
- Dr. Bennett M. Shapiro Co-Founder(age: 85, pay: $95,000)
- Mr. Spencer Ball Senior Vice President of HR
- Dr. George Farmer Ph.D. Chief Financial Officer
- Dr. David R. Elmaleh Co-Founder & Senior Advisor
- Dr. Joseph B. Bolen Chief Scientific Officer
- Dr. Bharatt M. Chowrira Pres, Chief of Bus. & Strategy and Executive Director
- Ms. Allison Mead Talbot Head of Communications & Investor Relations
-
Is PureTech Health founder-led company?
Yes, PureTech Health is a company led by its founders Ms. Daphne Zohar, Dr. Robert S. Langer Jr., Dr. Bennett M. Shapiro and Dr. David R. Elmaleh.
-
How many employees does PureTech Health have?
As Jul 2024, PureTech Health employs 90 workers, which is 19% less then previous quarter.
-
When PureTech Health went public?
PureTech Health plc is publicly traded company for more then 4 years since IPO on 16 Nov 2020.
-
What is PureTech Health's official website?
The official website for PureTech Health is puretechhealth.com.
-
Where are PureTech Health's headquarters?
PureTech Health is headquartered at 6 Tide Street, Boston, MA.
-
How can i contact PureTech Health?
PureTech Health's mailing address is 6 Tide Street, Boston, MA and company can be reached via phone at +61 74822333.
PureTech Health company profile:
PureTech Health plc
puretechhealth.comNASDAQ
90
Biotechnology
Healthcare
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Boston, MA 02210
CIK: 0001782999
ISIN: US7462371060
CUSIP: 746237106
